Charles Ryan, MD
Medical Oncology · Minneapolis, MNNPI 1083672000
Payments from drug & device makers
Across 150 payments — averaging $10,566 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1.1M
- Clovis Oncology, Inc.$236K
- Pfizer$95K
- Seagen Inc.$44K
- Incyte Corporation$30K
- Bayer$30K
- plus $78K from 16 others
Across 1 payment — averaging $33,093 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$33K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 7 | $1,071,499 |
| Clovis Oncology, Inc. | 32 | $236,046 |
| Pfizer | 29 | $94,795 |
| Seagen Inc. | 4 | $44,334 |
| Incyte Corporation | 6 | $30,480 |
| Bayer | 35 | $30,216 |
| Eli Lilly | 1 | $28,197 |
| Novartis | 7 | $9,811 |
| Advanced Accelerator Applications | 4 | $8,679 |
| Janssen Scientific Affairs, LLC | 4 | $6,540 |
| Tolmar, Inc. | 4 | $6,000 |
| Merck | 2 | $3,500 |
| Johnson & Johnson | 1 | $2,820 |
| Sumitomo Pharma America, Inc. | 2 | $2,708 |
| E.r. Squibb & Sons, L.L.C. | 1 | $2,700 |
| Dendreon Pharmaceuticals LLC | 1 | $2,175 |
| Exelixis Inc. | 2 | $2,026 |
| Janssen Research & Development, LLC | 2 | $1,750 |
| Astellas Pharma US Inc | 2 | $262 |
| AstraZeneca | 2 | $158 |
| Pharmaand GmbH | 1 | $100 |
| Progenics Pharmaceuticals, Inc. | 1 | $87 |
How this compares
$1,584,882 in reported general payments places this provider in the 75th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Minneapolis
- Emmanuel AntonarakisMinneapolis$6.9M
- Amy KrieMinneapolis$2.5M
- Keith SkubitzMinneapolis$1.1M
- Emil LouMinneapolis$458K
- Edward GreenoMinneapolis$415K
- Evidio Domingo MusibayMinneapolis$281K
- Evanthia GalanisRochester$72.3M
- Frank SinicropeRochester$10.3M
- Harry YoonRochester$10.2M
- Konstantinos LeventakosRochester$9.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.